Ozoralizumab showed comparable efficacy in rheumatoid arthritis patients with and without large joint involvement
Serum biomarkers identified as potential predictors of baricitinib response in juvenile idiopathic arthritis
Anti-CD38 antibody CM313 demonstrated manageable safety and encouraging efficacy in systemic lupus erythematosus
Nipocalimab demonstrated significant efficacy in moderate-to-severe Sjögren’s disease in phase 2 trial
